Etanercept-induced systemic lupus erythematosus

Clinical and Experimental Dermatology

Volumn 28, Issue 6, 2003, Pages 604-607

  Swale, V J ^a   Perrett, C M ^a   Denton, C P ^a   Black, C M ^a   Rustin, M H A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; BETAMETHASONE VALERATE; CYCLOSPORIN A; DNA ANTIBODY; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; INDOMETACIN; METHOTREXATE; MOMETASONE FUROATE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DERMATITIS; DIAGNOSTIC PROCEDURE; DISCOID LUPUS ERYTHEMATOSUS; DISEASE COURSE; ERYTHEMA; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPHOCYTOPENIA; MALE; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIAL VASCULITIS; VASCULITIS; VERTIGO;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 0242407011     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2003.01411.x     Document Type: Article

References (11)

1. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
2. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
3. Charles PJ, Smeenk RJDE, Jong J et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor-α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
4. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
5. Brion PH. Mittal-Henkel A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999; 131: 634.
6. Bleumink GS, ter Borg EJ, Ramselaar CG, Strickler BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40: 1317-9.
7. Shakoor N, Michalska M, Harris C, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80.
8. Ferraccioli GF, Assaloni R, Perin A. Drug-induced systemic lupus erythematosus and TNF-α blockers. Lancet 2002; 360: 645.
9. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanecerpt for rheumatoid arthritis. Ann Rheum Dis 2002; 61: 1031-2.
10. Pisetsky DS. Tumour necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000; 43: 2381-2.
11. Fautrel B, Foltz V, Frances C et al. Regression of subacute lupus erytthematosus in a pateint with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent. Arthritis Rheum 2002; 46: 1408-9.